Peptide-based blood coagulant - Haemostatix

Drug Profile

Peptide-based blood coagulant - Haemostatix

Alternative Names: Haemostasis therapeutic - Haemostatix; Haemostat topical - Haemostatix; PeproStat; PeproStat Liquid; Peptide-based antihaemorrhagic - Haemostatix

Latest Information Update: 03 Nov 2015

Price : $50

At a glance

  • Originator Haemostatix
  • Class
  • Mechanism of Action Fibrinogen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Surgical blood loss

Most Recent Events

  • 01 Jul 2014 Phase-I clinical trials in Surgical blood loss (Prevention) in United Kingdom (Topical, liquid)
  • 01 Jan 2014 Preclinical trials in Surgical blood loss (Prevention) in United Kingdom (Topical, patch)
  • 01 Jan 2014 Preclinical trials in Surgical blood loss (Prevention) in United Kingdom (Topical, paste)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top